137 related articles for article (PubMed ID: 9296333)
1. Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice.
Cincotta AH; Tozzo E; Scislowski PW
Life Sci; 1997; 61(10):951-6. PubMed ID: 9296333
[TBL] [Abstract][Full Text] [Related]
2. Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice.
Zhang Y; Scislowski PW; Prevelige R; Phaneuf S; Cincotta AH
Metabolism; 1999 Aug; 48(8):1033-40. PubMed ID: 10459570
[TBL] [Abstract][Full Text] [Related]
3. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists.
Scislowski PW; Tozzo E; Zhang Y; Phaneuf S; Prevelige R; Cincotta AH
Int J Obes Relat Metab Disord; 1999 Apr; 23(4):425-31. PubMed ID: 10340822
[TBL] [Abstract][Full Text] [Related]
4. Increased responsiveness of ventromedial hypothalamic neurons to norepinephrine in obese versus lean mice: relation to the metabolic syndrome.
Kraszewski KZ; Cincotta AH
Int J Mol Med; 2000 Apr; 5(4):349-55. PubMed ID: 10719049
[TBL] [Abstract][Full Text] [Related]
5. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice.
Liang Y; Lubkin M; Sheng H; Scislowski PW; Cincotta AH
Biochim Biophys Acta; 1998 Oct; 1405(1-3):1-13. PubMed ID: 9784590
[TBL] [Abstract][Full Text] [Related]
6. Dopamine receptor agonist reduces ethanol self-administration in the ethanol-preferring C57BL/6J inbred mouse.
Ng GY; George SR
Eur J Pharmacol; 1994 Nov; 269(3):365-74. PubMed ID: 7895775
[TBL] [Abstract][Full Text] [Related]
7. Increased responsiveness to the hyperglycemic, hyperglucagonemic and hyperinsulinemic effects of circulating norepinephrine in ob/ob mice.
Liang Y; Cincotta AH
Int J Obes Relat Metab Disord; 2001 May; 25(5):698-704. PubMed ID: 11360153
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice.
de Leeuw van Weenen JE; Parlevliet ET; Schröder-van der Elst JP; van den Berg SA; Willems van Dijk K; Romijn JA; Pijl H
Exp Diabetes Res; 2011; 2011():928523. PubMed ID: 21603181
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes.
Tavares G; Marques D; Barra C; Rosendo-Silva D; Costa A; Rodrigues T; Gasparini P; Melo BF; Sacramento JF; Seiça R; Conde SV; Matafome P
Mol Metab; 2021 Sep; 51():101241. PubMed ID: 33933677
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice.
Bina KG; Cincotta AH
Neuroendocrinology; 2000 Jan; 71(1):68-78. PubMed ID: 10644901
[TBL] [Abstract][Full Text] [Related]
11. Dopamine-mediated behaviours produced in naive mice by bromocriptine plus SKF 38393.
Jackson DM; Ross SB; Hashizume M
J Pharm Pharmacol; 1988 Mar; 40(3):221-3. PubMed ID: 2899159
[TBL] [Abstract][Full Text] [Related]
12. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes.
Ohta K; Kuno S; Mizuta I; Fujinami A; Matsui H; Ohta M
Life Sci; 2003 Jun; 73(5):617-26. PubMed ID: 12770616
[TBL] [Abstract][Full Text] [Related]
13. Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs.
Cho S; Neff NH; Hadjiconstantinou M
Eur J Pharmacol; 1997 Apr; 323(2-3):149-57. PubMed ID: 9128833
[TBL] [Abstract][Full Text] [Related]
14. Levodopoa but not bromocriptine induces AP-1 and creb DNA-binding activity in the dopamine-depleted striatum of the rat.
Kashihara K; Akiyama K; Ishihara T; Shiro Y; Shohmori T
Life Sci; 1996; 58(10):PL 159-70. PubMed ID: 8602107
[TBL] [Abstract][Full Text] [Related]
15. Working memory span capacity improved by a D2 but not D1 receptor family agonist.
Tarantino IS; Sharp RF; Geyer MA; Meves JM; Young JW
Behav Brain Res; 2011 Jun; 219(2):181-8. PubMed ID: 21232557
[TBL] [Abstract][Full Text] [Related]
16. Dopamine modulates synaptic transmission between rat olfactory bulb neurons in culture.
Davila NG; Blakemore LJ; Trombley PQ
J Neurophysiol; 2003 Jul; 90(1):395-404. PubMed ID: 12611989
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of dopamine receptor subtype-specific agonists with respect to operant behavior maintained on a differential reinforcement of low-rate responding (DRL) schedule.
Chiang FK; Cheng RK; Liao RM
Pharmacol Biochem Behav; 2015 Mar; 130():67-76. PubMed ID: 25584855
[TBL] [Abstract][Full Text] [Related]
18. The ameliorative effects and underlying mechanisms of dopamine D1-like receptor agonist SKF38393 on Aβ
Zang X; Cheng ZY; Sun Y; Hua N; Zhu LH; He L
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():250-261. PubMed ID: 28939187
[TBL] [Abstract][Full Text] [Related]
19. Activation of D1 and D2 dopamine receptors increases the activity of the somatostatin receptor-effector system in the rat frontoparietal cortex.
Izquierdo-Claros RM; del Boyano-Adánez M; Arilla-Ferreiro E
J Neurosci Res; 2000 Oct; 62(1):91-8. PubMed ID: 11002291
[TBL] [Abstract][Full Text] [Related]
20. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
Ralph RJ; Caine SB
J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
